Earnings Call · Q2 FY2023·2023-08-03

Q2 23EPS -43.40%·Rev n/aQ1 23EPS -47.73%·Rev n/aQ4 22EPS 0.00%·Rev n/aQ3 22EPS +11.11%·Rev n/a⚠ consensus missing

Definium Therapeutics, Inc. DFTX

Rob Barrow — Chief Executive Officer

Schond Greenway — Chief Financial Officer

−7.6%1d on move date−7.2% vs SPY3d−7.9%5d−8.9%

Research tier

Behavioral profile computed for 2 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more DFTX calls or request research access.

More DFTX calls Browse calls Request research access